JP2024513713A5 - - Google Patents

Info

Publication number
JP2024513713A5
JP2024513713A5 JP2023557116A JP2023557116A JP2024513713A5 JP 2024513713 A5 JP2024513713 A5 JP 2024513713A5 JP 2023557116 A JP2023557116 A JP 2023557116A JP 2023557116 A JP2023557116 A JP 2023557116A JP 2024513713 A5 JP2024513713 A5 JP 2024513713A5
Authority
JP
Japan
Prior art keywords
seq
sequence
chimeric antigen
antigen receptor
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513713A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/052443 external-priority patent/WO2022195535A1/en
Publication of JP2024513713A publication Critical patent/JP2024513713A/ja
Publication of JP2024513713A5 publication Critical patent/JP2024513713A5/ja
Pending legal-status Critical Current

Links

JP2023557116A 2021-03-19 2022-03-17 クローディン-3を標的とするキメラ抗原受容体および癌を治療する方法 Pending JP2024513713A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163217P 2021-03-19 2021-03-19
US63/163,217 2021-03-19
PCT/IB2022/052443 WO2022195535A1 (en) 2021-03-19 2022-03-17 Chimeric antigen receptors targeting claudin-3 and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2024513713A JP2024513713A (ja) 2024-03-27
JP2024513713A5 true JP2024513713A5 (cg-RX-API-DMAC7.html) 2025-03-26

Family

ID=80937091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557116A Pending JP2024513713A (ja) 2021-03-19 2022-03-17 クローディン-3を標的とするキメラ抗原受容体および癌を治療する方法

Country Status (10)

Country Link
US (1) US20230192842A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308605A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024513713A (cg-RX-API-DMAC7.html)
KR (1) KR20230160307A (cg-RX-API-DMAC7.html)
CN (2) CN117377691A (cg-RX-API-DMAC7.html)
AR (1) AR125136A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018987A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212615A1 (cg-RX-API-DMAC7.html)
TW (1) TW202304960A (cg-RX-API-DMAC7.html)
WO (1) WO2022195535A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240176948A (ko) * 2023-06-15 2024-12-26 에이비온 주식회사 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
ES2778651T3 (es) * 2015-10-09 2020-08-11 Miltenyi Biotec Technology Inc Receptores de antígeno quimérico y métodos de uso
FR3044016A1 (fr) 2015-11-24 2017-05-26 Glaxosmithkline Ip Dev Ltd Lignees cellulaires stables pour la production retrovirale
KR102067352B1 (ko) 2015-11-24 2020-01-16 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 레트로바이러스 생산을 위한 일시적인 형질감염 방법
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
KR102340989B1 (ko) * 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
KR20210037581A (ko) * 2019-09-26 2021-04-06 (재)록원바이오융합연구재단 항-클라우딘-3 키메라 항원 수용체

Similar Documents

Publication Publication Date Title
JP2021527409A5 (cg-RX-API-DMAC7.html)
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
CN110831965B (zh) 靶向hiv gp120和cd3的多特异性抗体
ES2801873T3 (es) Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos
AU2016347058B2 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection
JP2018526028A5 (cg-RX-API-DMAC7.html)
JP2025028239A5 (cg-RX-API-DMAC7.html)
JP2024532485A5 (cg-RX-API-DMAC7.html)
JP2022537159A5 (cg-RX-API-DMAC7.html)
US20240052052A1 (en) Novel anti-cd24 antibodies
JP2021522162A5 (cg-RX-API-DMAC7.html)
CN111148761A (zh) 多特异性抗体及其制备和使用方法
JP2021535758A5 (cg-RX-API-DMAC7.html)
IL271257B2 (en) Multi-specific antibodies and methods of making and using thereof
WO2022152168A1 (zh) 靶向ror1的抗体及其用途
JP2023539591A5 (cg-RX-API-DMAC7.html)
JP2021524451A (ja) 最適化済みgp41結合分子及びその使用
CN119546343A (zh) 细胞因子融合蛋白与cd8抗原结合分子的组合
CN114437214A (zh) 靶向lir1的抗体及其用途
JP2025504398A5 (cg-RX-API-DMAC7.html)
WO2023131063A1 (zh) 特异性结合msln的嵌合抗原受体及其应用
JP2022550120A5 (cg-RX-API-DMAC7.html)
KR20260062933A (ko) 항-γδ TCR 항체 및 이의 용도
HK40111322A (en) Multi-specific antibodies and methods of making and using thereof
WO2025232896A1 (zh) 药物组合及用途